Table 3.

Clinically meaningful changes in BCVA, time to onset, and time to resolution in patients receiving belamaf (2.5 mg/kg) in DREAMM-2

	BCVA of 20/50 or worse in the better-seeing eye (n = 95)a	BCVA of 20/200 or worse in the better-seeing eye (n = 95)b
n (%)	17 (18)	1 (1)
Median time to onset (range), days	66.0 (20–442)	21.0 (21–21)
Event outcomes as of last follow-up, n/N (%)
Recovered	14/17 (82)c	1/1 (100)d
Not recovered	3/17 (18)	0
Median time to resolution in patients who recovered as of last follow-up (range), days	n = 14	n = 1
	21.5 (7–64)	22.0 (22–22)

Safety population (n = 95) defined as all patients who received ≥ 1 dose of belamaf. Data represent BCVA changes in the patients’ better-seeing eye

BCVA best-corrected visual acuity

^aBetter than 20/50 at baseline in the better-seeing eye and 20/50 or worse post baseline in the better-seeing eye

^bBetter than 20/200 at baseline in the better-seeing eye and 20/200 or worse post baseline in the better-seeing eye

^cRecovery was defined as 20/40 or better in the better-seeing eye

^dRecovery was defined as better than 20/200 in the better-seeing eye